83278-86-8

Basic information

• Product Name: 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL
• Synonyms: 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL;2-HYDROXYMETHYLCHROMANE;Chroman-2-yl-methanol;2-(Hydroxymethyl)chroman 97%;(3,4-Dihydro-2H-chromen-2-yl)methanol, (3,4-Dihydro-2H-1-benzopyran-2-yl)methanol;3,4-dihydro-2H-1-benzopyran-2-ylMethanol;2-(Hydroxymethyl)chroman97%
• CAS NO: 83278-86-8
• Molecular Formula: C₁₀H₁₂O₂
• Molecular Weight: 164.2
• Product Categories: Hydroxymethyl's;Fused Ring Systems
• Mol File: 83278-86-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 44 °C
• Boiling Point: 293.2 °C at 760 mmHg
• Flash Point: 133.9 °C
• Appearance: /
• Density: 1.125 g/cm³
• Storage Temp.: 2-8°C
• PKA: 14.18±0.10(Predicted)
• CAS DataBase Reference: 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL(83278-86-8)
• EPA Substance Registry System: 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL(83278-86-8)

Safety Data

• Hazardous Substances Data: 83278-86-8(Hazardous Substances Data)

Usage

General Description

3,4-Dihydro-2H-chromen-2-ylmethanol is a chemical compound with a molecular formula C10H12O2. It is a type of chromene derivative that contains a chroman ring system. 3,4-DIHYDRO-2H-CHROMEN-2-YLMETHANOL has potential pharmaceutical applications, particularly in the development of new drugs for various purposes. It may exhibit antioxidant, anti-inflammatory, and antifungal properties, making it a target for further research and development. Its unique chemical structure and potential biological activities make it an interesting compound for the scientific community to explore and potentially harness for various medical and industrial applications.

Upstream product

• 51939-71-0 chroman-2-carboxylic acid 
• 24698-77-9 ethyl Chroman-2-carboxylate 
• 59363-19-8 4-(2-Chloro-phenyl)-butane-1,2-diol 
• 694-80-4 2-bromo-1-chlorobenzene 
• 83780-47-6 (-)-(R)-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 
• 66598-81-0 chroman-2-carboxylic acid methyl ester 
• 4940-39-0 acide chromone carboxylique-2 
• 543-27-1 isobutyl chloroformate 

Downstream Products

• 104605-88-1 3,4-dihydro-2H-1-benzopyran-2-methanol 4-methylbenzenesulfonate (ester) 
• 99290-94-5 1-Chroman-2-ylmethyl-piperidine 

Relevant articles and documents

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS

The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.

Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform

This paper examines the relative effectiveness of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II (CA-II). Topiramate (1) and its sulfamide analogue 4, and 4,5-cyclic sulfate 6 and its sulfamide analogue 5, were compared for inhibition of human CA-II. A colorimetric assay, based on the pH shift that accompanies hydration of carbon dioxide, and an esterase assay were used. For these bioisosteric pairs, 1/4 and 6/5, the sulfamate compound was markedly more potent than its sulfamide counterpart. A similar, large difference in potency was also observed for the sulfamate/sulfamide pairs 14/15 and 16/17. These results indicate that the sulfamide moiety is not particularly suitable for obtaining potent carbonic anhydrase inhibition. A discussion of this structure-activity relationship with respect to the interactions of 1 and 6 with CA-II from published X-ray data is presented. A metabolic acidosis study was performed in rats with 1, 4, 6, and 2, and the results are discussed with respect to the degree of inhibition of CA-II in vivo.